Ondansetron Baxter

Ondansetron, the active ingredient in Ondansetron Baxter, is a 5-HT3 receptor antagonist presented as a 4 mg oral tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiotherapy and surgery in adult and paediatric patients.

GNH USA supplies Ondansetron Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Baxter is a selective 5‑HT3 receptor antagonist used in the prevention and treatment of nausea and vomiting across several clinical pathways. - Chemotherapy‑induced nausea and vomiting: helps control acute and delayed episodes in cancer patients receiving cytotoxic therapy. - Radiotherapy‑induced nausea and vomiting: reduces vomiting associated with abdominal or pelvic radiation. - Post‑operative nausea and vomiting: decreases the incidence of nausea after general anaesthesia. - Pregnancy‑related hyperemesis gravidarum (when other therapies are ineffective): provides symptomatic relief under specialist supervision.

Adverse reactions to ondansetron are generally dose‑related and may vary with the route of administration.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with intravenous use. - Severe hypersensitivity: rash, itching, swelling or anaphylaxis. - Serotonin syndrome: agitation, hyperreflexia, fever when combined with other serotonergic agents. - Hepatic enzyme elevation: increased ALT/AST levels. - Vision changes: blurred vision or transient visual disturbances.

When prescribing ondansetron, clinicians should consider patient‑specific factors and follow standard safety practices. - Cardiac assessment: obtain baseline ECG in patients with known cardiac disease or electrolyte imbalance. - Electrolyte monitoring: correct hypokalaemia or hypomagnesaemia before use. - Drug‑interaction review: avoid concurrent use with other QT‑prolonging agents. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated. - Renal/hepatic impairment: dose adjustment may be required in severe dysfunction. - Store at below 25°C: keep in the original container, protect from moisture and light.

Ondansetron can modify the pharmacokinetics or cardiac safety profile of several medicines.

Major Interactions (Avoid): - Aprepitant + ondansetron: additive QT prolongation risk. - Certain anti‑malarial drugs (e.g., quinine): may increase QT interval. - Tramadol: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): monitor for serotonin syndrome. - Antifungal azoles (ketoconazole, fluconazole): may raise ondansetron plasma levels. - Macrolide antibiotics (erythromycin, clarithromycin): modest QT prolongation potential.